Literature DB >> 34216133

Range of Varicella Zoster Co-Infections with COVID-19, Singapore.

Jerold Loh1, Sai Meng Tham2,3, Paul Anantharajah Tambyah2,3, Gabriel Yan2,3,4, Chun Kiat Lee5, Louis Yi Ann Chai2,3.   

Abstract

There have been recent descriptions of the novel coronavirus disease 2019 (COVID-19) presenting as 'varicella-like exanthem'. We report three cases of patients with Varicella-Zoster Virus (VZV) and COVID-19 co-infections, presenting in three varied ways. These cases highlight the need for heightened alertness to how such co-infections can present, to pick up overlapping 'dual pathologies' during this current pandemic given that infection control measures including airborne precautions are crucial for both COVID-19 and VZV.
Copyright © 2021 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS.

Entities:  

Keywords:  COVID-19; Chickenpox; Coinfection; Communicable diseases; Public health

Year:  2021        PMID: 34216133      PMCID: PMC8258286          DOI: 10.3947/ic.2020.0154

Source DB:  PubMed          Journal:  Infect Chemother        ISSN: 1598-8112


Introduction

There have been recent descriptions of the novel coronavirus disease (COVID-19) presenting with ‘varicella-like exanthema’ [12]. Initial queries had been if such papulovesicular eruptions could be herpes simplex virus or varicella zoster virus (VZV) co-manifesting with COVID-19 [34]; though dual simultaneous viral infections would be unusual. Herein we describe 3 patients diagnosed with VZV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infections with varying presentations.

Case report

Patient 1, 39-year-old male presented with fever and generalized pruritic vesicular rash of 3 days, in a head-to-centripetal distribution (Fig. 1A, 1B). He also tested for nasopharyngeal SARS-CoV-2 by polymerase chain reaction (PCR) (cobas SARS-CoV-2 Test; Roche Molecular Systems, Branchburg, NJ, USA) due to known exposure (Ct value- E gene: 35.76). On day 4 he deteriorated requiring supplemental oxygen. Thoracic imaging showed pulmonary nodules consistent with varicella pneumonia (Fig. 1C, 1D). The vesicular fluid tested positive for varicella DNA by PCR (VZV ELITe MGB® Kit; ELITechGroup, Puteaux, France); his sera was VZV IgM and IgG positive.
Figure 1

Clinical Features of Patients with Varicella and COVID-19 Co-infections.

(A) Clinical Photograph, Patient 1, Vesicular rash on face. (B) Clinical Photograph, Patient 1, Vesicular rash on trunk. (C) Computed Tomography Thorax, Patient 1. (D) Computed Tomography Thorax, Patient 1. (E) Clinical Photograph, Patient 3, Papulo-vesicular rash on face. (F) Clinical Photograph, Patient 3, Papulo-vesicular rash on trunk.

Clinical Features of Patients with Varicella and COVID-19 Co-infections.

(A) Clinical Photograph, Patient 1, Vesicular rash on face. (B) Clinical Photograph, Patient 1, Vesicular rash on trunk. (C) Computed Tomography Thorax, Patient 1. (D) Computed Tomography Thorax, Patient 1. (E) Clinical Photograph, Patient 3, Papulo-vesicular rash on face. (F) Clinical Photograph, Patient 3, Papulo-vesicular rash on trunk. Patient 2, 24-year-old male presented with 2 days of fever, cough and pruritic vesicular rash, again from a head-to-centripetal distribution. He had potential COVID-19 exposure distinct from Patient 1 and was SARS-CoV-2 PCR positive (Ct value- E gene: 35.76). The vesicular fluid PCR detected varicella DNA but was negative for SARS-CoV-2. Patient 3, 32-year-old male had fever and cough for 2 days. He was positive for SARS-CoV-2 via nasopharynx PCR (Ct value- E gene: 35.15), but developed generalized papulo-vesicular rash one week later (Fig. 1E, 1F). The patient declined vesicular and blood sampling. Primary varicella was diagnosed clinically based on classical morphological evolution and centripetal distribution. All the patients had no common epidemiological contact. They were unacquainted; had resided and worked at different locations. All were given acyclovir with improvement. These cases beget the question whether SARS-CoV-2 infection attenuates host immunity, modulates host antiviral lymphocyte function and potentiates susceptibility to opportunistic pathogens [5]. Conversely hyperinflammatory states, recognized in SARS-CoV-2 infection [6], can be a trigger to uncover latent susceptibilities to Mycobacteria or Varicella [789]. However, circulating interleukin-6 incidentally measured for Patient 1 was not elevated at 8.8 pg/mL (normal 1 - 10 pg/mL). The study was approved by the Institutional Review Board of the National Healthcare Group, Singapore (Approval number: DSRB 2021/00513). Written consent was obtained in each case for use of medical information in this report (Patient 2 declined photo documentation).

Discussion

We demonstrate the range of clinical presentations in COVID-19-VZV co-infections. Patient 1 had predominant VZV manifestation. Patient 2 had classical VZV skin lesions with upper respiratory symptom from onset. Dermatological presentation of Patient 3 was delayed, one week after COVID-19 diagnosis; similar to patients described by Marzano et al. [1]. Densely-populated locations promote co-transmission of highly infectious pathogens like SARS-CoV-2 and VZV. This can account for occurrence of co-infections epidemiologically short of invoking pathogen-evoked immunomodulation posing public health risks in living spaces like dormitories and community isolation facilities. These cases highlight the need for heightened alertness to pick up overlapping ‘dual pathologies’ during this current pandemic.
  9 in total

Review 1.  Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.

Authors:  Jay A Fishman; John I Hogan; Marcela V Maus
Journal:  Clin Infect Dis       Date:  2019-08-30       Impact factor: 9.079

2.  On tuberculosis and COVID-19 co-infection.

Authors:  Marina Tadolini; José-María García-García; François-Xavier Blanc; Sergey Borisov; Delia Goletti; Ilaria Motta; Luigi Ruffo Codecasa; Simon Tiberi; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2020-08-20       Impact factor: 16.671

3.  Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients": To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out.

Authors:  Mar Llamas-Velasco; Pedro Rodríguez-Jiménez; Pablo Chicharro; Diego De Argila; Patricia Muñoz-Hernández; Esteban Daudén
Journal:  J Am Acad Dermatol       Date:  2020-05-20       Impact factor: 11.527

4.  Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients": Discussing specificity.

Authors:  Daniel Ortega-Quijano; Juan Jimenez-Cauhe; Patricia Burgos-Blasco; Natalia Jimenez-Gomez; Diego Fernandez-Nieto
Journal:  J Am Acad Dermatol       Date:  2020-05-04       Impact factor: 11.527

5.  Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients.

Authors:  Angelo Valerio Marzano; Giovanni Genovese; Gabriella Fabbrocini; Paolo Pigatto; Giuseppe Monfrecola; Bianca Maria Piraccini; Stefano Veraldi; Pietro Rubegni; Marco Cusini; Valentina Caputo; Franco Rongioletti; Emilio Berti; Piergiacomo Calzavara-Pinton
Journal:  J Am Acad Dermatol       Date:  2020-04-16       Impact factor: 11.527

6.  Four Patients with COVID-19 and Tuberculosis, Singapore, April-May 2020.

Authors:  Sai Meng Tham; Wei Yang Lim; Chun Kiat Lee; Jerold Loh; Arthi Premkumar; Benedict Yan; Adrian Kee; Louis Chai; Paul Anantharajah Tambyah; Gabriel Yan
Journal:  Emerg Infect Dis       Date:  2020-07-15       Impact factor: 6.883

7.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

8.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

9.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients.

Authors:  Meijuan Zheng; Yong Gao; Gang Wang; Guobin Song; Siyu Liu; Dandan Sun; Yuanhong Xu; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

  9 in total
  2 in total

1.  Oral Herpes Zoster Infection Following COVID-19 Vaccination: A Report of Five Cases.

Authors:  Hiroshi Fukuoka; Nobuko Fukuoka; Toshiro Kibe; R Shane Tubbs; Joe Iwanaga
Journal:  Cureus       Date:  2021-11-10

Review 2.  Characteristics of herpes zoster infection in patients with COVID-19: a systematic scoping review.

Authors:  Torrey Czech; Yoshito Nishimura
Journal:  Int J Dermatol       Date:  2022-05-03       Impact factor: 3.204

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.